Clinical trial
A Phase I, Randomized, Double-blind, Placebo-controlled, Single, and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Vitalangio1 in Venous Thromboembolism Patients and a Randomized, Open-label, 2-period Crossover Liver Effect Study
NCT07618351 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Double-blind, Placebo-controlled, Single, and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Vitalangio1 in Venous Thromboembolism Patients and a Randomized, Open-label, 2-period Crossover Liver Effect Study
- Lead sponsor
- Peking University First Hospital
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 20, 2023
- Completion date
- March 12, 2026
- Enrollment
- 627 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.